🔗 Share this article

Given that the US continues making historic revisions to its vaccine recommendations, one figure has emerged in a surprising turn: Høeg, a Danish American physician and public health researcher who initially gained attention by questioning COVID-19 shots throughout the global health crisis and has zeroed in on possible fatalities after Covid immunization in her brief position at the Food and Drug Administration.

Proposed Changes to Childhood Immunization Schedule

Agency leaders were set to reveal sweeping revisions to the pediatric immunization program in December, synchronizing the US with the Danish national calendar, sources say – a major change that would place the US at odds with many the global community with no evidence for improved outcomes. This reveal has been postponed until the new year.

Rather than the director of the vaccine center, Høeg is listed to address the audience at the event. She was just designated temporary leader of the FDA’s CDER, the fifth individual to run the office this calendar year.

A Shift at the Regulatory Body

Høeg's temporary position could signify a closer partnership between the pharmaceutical and biologics branches as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it suggests a greater focus upon dismantling already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for halting some childhood vaccine recommendations in the US in order to be more similar to Denmark, a country with universal health coverage and a number of inhabitants about the population of the state of Wisconsin.

In her initial statements, she has continued to focus on vaccines – usually the purview of Dr. Prasad, chief of the FDA’s CBER – rather than pharmaceutical oversight.

Doubts Over Expertise

The appointee has little discernible track record in medication creation, regulation or management, which has been customary for past heads of the biologics center. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“She appears not to have the necessary background” for overseeing the CDER, stated Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in leading a sizeable institution. She has no expertise in industry regulation.”

Former directors of CBER would “understand regulatory frameworks and the research of drug development”, noted Janet Woodcock. “Clearly, she lacks the kind of background that previous people who headed the center have had.”

This division has an vast workload at the FDA, the former commissioner emphasized.

“Many people just focuses on the novel medication approvals, but the generic program approves thousands of generic drugs. There is also a biologic copycat branch, non-prescription drug unit and other areas, and each of these have to be managed,” she noted. “The area you neglect, that is precisely what that I always told people is going to cause problems.”

Additionally, a major management aspect to the position, which supervises in excess of 5,000 employees. “It is a huge administrative position, if you execute it properly,” the former official concluded.

Response and Controversial Policies

Regarding concerns about Høeg’s qualifications and whether this appointment indicates greater collaboration among FDA leaders on immunizations, a representative said that the “questions are based on inaccurate presumptions”.

“Her resume is consistent with the responsibilities of her role,” the representative explained, citing the period Høeg spent guiding the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg inherits the commissioner’s controversial expedited review system, a disputed one-day medication authorization process that apparently worried her former heads. “How are these drugs being chosen for this voucher program? Who makes the decisions?” Dr. Howard asked. “There is a lot of lack of transparency going on at the FDA right now.”

Overall, he said, “the agency looks to be trending towards less stringent regulations of most medications, except for immunizations.”

Documented Track Record on Immunizations

With immunizations, Høeg has a more documented, if concerning, history, critics said. She published a analysis using unverified public submissions to determine the incidence of heart inflammation following COVID-19 immunization. She advised the Florida chief medical officer Dr. Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccines are pose a greater threat than they are.

Included in her “wish list” for the current administration featured revising rules for recently developed shots and ending “optional” immunizations, she said post-election on a podcast. At the FDA, Dr. Høeg has allegedly floated the idea of barring adolescent males from obtaining COVID-19 vaccinations.

“She’s an thorough dogmatist who begins with her preconceived notions and works backwards to fit the evidence in a highly misleading, fraudulent manner,” Dr. Howard said.

Taking Control and a “Revenge Tour”

Høeg became part of other dissenters, {like|